Trump slaps 100% tariff on generic drugs in US manufacturing push

Generic drug manufacturers face huge penalties if they fail to relocate production to the US within two years, with India among the countries expected to be hardest hit.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

UK Prime Minister axes science ministry in govt shakeup

22 July 2026 Plans to merge the UK’s standalone science ministry into an expanded business department, coupled with the departure of the Science Minister, mark a change in the country’s approach to science and innovation.

Regulation & Industry

Why is 2026 already a record year for M&A activity?

17 July 2026 Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture.

Regulation & Industry

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

14 July 2026 An enhanced agreement between the two countries cements existing protections for pharma innovators and is being hailed by the industry as a boost for investment and research.

More features

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

UK Prime Minister axes science ministry in govt shakeup

Masimo keeps $634m smartwatch award and moves to appeal

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

Why is 2026 already a record year for M&A activity?

Illumina ordered to recall products after German patent ruling

Goodwin launches San Diego office with senior life sciences hire

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer

Trump slaps 100% tariff on generic drugs in US manufacturing push

More on this story

Editor's picks

Editor's picks

More features